Reduction of murine osteosarcoma lung metastases using the dipeptidyl peptidase inhibitor talabostat.

@article{Kim2006ReductionOM,
  title={Reduction of murine osteosarcoma lung metastases using the dipeptidyl peptidase inhibitor talabostat.},
  author={S. Kim and S. Cohen and J. Epps and J. Smedley and A. Mendoza and C. Khanna and B. Jones and N. Aziz and L. Helman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={9009}
}
  • S. Kim, S. Cohen, +6 authors L. Helman
  • Published 2006
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 9009 Background: Dipeptidyl peptidases comprise a family of serine proteases that includes the genes dipeptidyl peptidase IV (DPP-IV) and fibroblast activation protein (FAP). FAP is expressed in stromal fibroblasts that surround sites of metastatic carcinomas, but not in the tumor cells themselves. Talabostat (valine-proline-boronic acid) is a potent and long-acting inhibitor of dipeptidyl peptidases. It has previously been shown to have anti-tumor activity in preclinical studies. We utilized… CONTINUE READING
    View on PubMed
    doi.org